Iceni Pharmaceuticals benefits greatly from an enthusiastic and dynamic team of professionals, backed up by an outstanding commercial, medical and regulatory expert advisory panel. Three of Iceni's team already have extensive first hand clinical development experience of cilengitide under a previous Merck Serono-sponsored glioblastoma treatment program.
John has been involved in biotechnology commercialisation since 2007, when he set up BigDNA Ltd as an academic spin out. Since that time he has raised more than £4.3M of equity funding and was instrumental in licensing out BigDNA’s phage-based DNA vaccine technology to Eli Lilly animal health. Click for Bio
Rhys brings more than 15 years’ experience in commercialisation of life science research in both academia and industry around the world, including previous roles with Origen Therapeutics and MerseyBIO, and he now advises a number of UK and international companies. Click for Bio